Teduglutide

Key Benefits#

• Increases intestinal villus height and absorption surface area
• Reduces intestinal permeability (leaky gut)
• FDA-approved for short bowel syndrome
• Reduces parenteral nutrition dependence in SBS patients
• Promotes intestinal mucosal healing in IBD
• Increases tight junction proteins ZO-1 and occludin

Mechanism of Action#

Teduglutide binds GLP-2 receptors in intestinal crypt cells to stimulate mucosal proliferation, reduce apoptosis, and promote intestinal adaptation. It increases blood flow to the gut, enhances tight junction protein expression (reducing intestinal permeability), and upregulates growth factors including EGF and IGF-1 in the intestinal wall.

Dosing Protocols#

Side Effects#

• Injection site reactions
• Abdominal pain and bloating
• Nausea
• Risk of intestinal polyp growth (requires colonoscopy surveillance)
• Fluid retention

Storage#

Refrigerate at 2-8°C. Do not freeze. Single-use vials.

Featured In Stacks#

1. 1.
   Interpreting pooled GLP-2 analogue effects in chronic intestinal failure transparency, attrition, and real-world generalisability

   Gupta R, Nainwal P, Padhi S, Srinivasan H · Clinical nutrition ESPEN · 2026PubMed Verified

2. 2.
   Systemic Pharmacokinetic Principles of Therapeutic Peptides

   Nordell P, Jansson-Löfmark R, Gennemark P · Clinical pharmacokinetics · 2026PubMed Verified

3. 3.
   Double-balloon enteroscopy evaluation and surveillance in patients with short bowel syndrome

   Scaramella L, Sorge A, Tontini GE, Fracas E, Smania V, Costantino A et al. · Therapeutic advances in gastroenterology · 2026PubMed Verified

4. 4.
   Drug-induced intestinal obstruction: insights from the FDA Adverse Event Reporting System

   Li H, Li Y, Liu L, Zeng B, Su S, Liu J et al. · Therapeutic advances in drug safety · 2026PubMed Verified

5. 5.
   Low-digestible glucans promote rapid recovery from 5-fluorouracil-induced small intestinal villous atrophy while enhancing glucagon-like peptide-2 secretion in rats

   Nishina R, Hino S, Kato C, Nishimura N · Nutrition research (New York, N.Y.) · 2026PubMed Verified

6. 6.
   Real-world efficacy of long-term teduglutide use in pediatric patients with short bowel syndrome

   Josey C, Mazariegos G, King E, Holzer P, Rudolph J, Raghu VK · Intestinal Failure (New York, N.Y.) · 2025PubMed Verified

7. 7.
   Personalized drug screening and risk assessment in patient-derived gastroenteropancreatic neuroendocrine neoplasms

   Auernhammer CJ, Wang K, Maccio U, Knösel T, Hungbauer MP, Schilbach K et al. · The Journal of clinical endocrinology and metabolism · 2026PubMed Verified

8. 8.
   Impact of teduglutide on pediatric short bowel syndrome: A systematic review and trial sequential meta-analysis

   Jiao P, Zhang ZJ, Jiang Y, Zhou J, Deng KH, Zhu WX et al. · World journal of gastrointestinal surgery · 2025PubMed Verified

9. 9.
   Teduglutide in pediatric patients under 10 kg with short bowel syndrome on parenteral support: An open-label study

   Masumoto K, Muto M, Sasaki T, Shikamura M, Tanaka T, Sakui S et al. · Pediatrics international : official journal of the Japan Pediatric Society · 2026Clinical TrialPubMed Verified

10. 10.
    Loss of GLP-2R signaling in Glp2r(-/-) mice increases the long-term severity of graft versus host disease

    Yusta B, Wong CK, Matthews D, Koehler JA, Baggio LL, Drucker DJ · Molecular metabolism · 2026PubMed Verified

11. 11.
    Real-world effectiveness and safety of teduglutide in adult and pediatric patients with short bowel syndrome in Argentina

    Solar Muñiz H, Fernández A, Busoni V, Martínez MI, Rumbo C, De Barrio S et al. · World journal of gastrointestinal pharmacology and therapeutics · 2025PubMed Verified

12. 12.
    Positive clinical outcomes associated with use of glucagon-like peptide-2 (GLP-2) analogues in patients with intestinal failure: A systematic review and meta-analysis

    Bastas A, Williams K, Wong D · Clinical nutrition ESPEN · 2026Meta-AnalysisPubMed Verified

13. 13.
    Six-Month Safety and Effectiveness of Teduglutide in Patients with Short Bowel Syndrome in Japan: Interim Analysis of Post-marketing Surveillance

    Wada M, Nakamura S, Hayashi A, Otake R, Miyamoto M, Tanaka T · Advances in therapy · 2026PubMed Verified

14. 14.
    3, 2, 1! From GLP-2 to GLP-1 analog over a 10-year journey

    Tapia-Sanchiz MS, Sampedro-Núñez MA, Jiménez-Blanco S, Molina-Baena B · Endocrinologia, diabetes y nutricion · 2026Case ReportPubMed Verified

15. 15.
    Delayed presentation of a retained colonic segment in a child with intestinal failure on teduglutide

    Bordelon RC, Varalla SJ, Tammisetti VS, Shahin MM, Tchakarov A, Imseis E et al. · JPGN reports · 2025PubMed Verified

16. 16.
    Development of a consensus parenteral solution weaning algorithm for children with short-bowel syndrome associated intestinal failure responding to teduglutide therapy

    Eldredge JA, Borg C, Couper RTL, Dehlsen K, Ee LC, Fox J et al. · Archives of disease in childhood · 2026PubMed Verified

17. 17.
    Safety of Teduglutide for Managing Patients with Short Bowel Syndrome: A Systematic Review and Meta-analysis

    Liu S, Yu X, Ye F, Jiang L · Pakistan journal of medical sciences · 2025ReviewPubMed Verified

18. 18.
    A real-world pharmacovigilance assessment of drug-related carcinoembryonic antigen increase

    Du C, Liang Y, Liu W, Jiang Y, Wang Y · Medicine · 2025PubMed Verified

19. 19.
    A case report on the long-term use of teduglutide in a pediatric patient with short bowel syndrome

    Sakurai T, Kudo H, Megumi N, Ando R, Kazama T, Okubo R et al. · Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2025PubMed Verified

20. 20.
    Efficacy of Teduglutide in Pediatric Short Bowel Syndrome: Association with Citrulline Levels and Anatomical Location of Remnant Small Intestine

    Goto Y, Masumoto K, Sasaki T, Shirane K, Aoyama T, Sakamoto N et al. · Children (Basel, Switzerland) · 2025PubMed Verified

21. 21.
    Teduglutide

    2006ReviewPubMed Verified

22. 22.
    Longitudinal single-cell analysis of glucagon-like peptide-2 treatment in patients with short bowel syndrome

    Kudo Y, Miyamoto K, Suzuki S, Chida A, Tojo A, Hasegawa M et al. · JCI insight · 2025PubMed Verified

23. 23.
    Teduglutide treatment during breast feeding in a patient with intestinal failure: a case report

    Lillienau J, Nilsson E, Vulcan A, Nilsson Å · Frontiers in nutrition · 2025Case ReportPubMed Verified

24. 24.
    Quality of life and lived experience of patients with short bowel syndrome treated with teduglutide and weaning off home parenteral nutrition: a qualitative analysis of patient diaries

    Jurewitsch B, Peters C, Okamoto C · BMJ open gastroenterology · 2025PubMed Verified

25. 25.
    Reduction of Parenteral Nutrition in Children with Short Bowel Syndrome Treated with Teduglutide: Experience from the Czech Republic

    Peskova S, Sulakova A, Bajerova K, Schwarz J, Melek J, Karaskova E et al. · Klinische Padiatrie · 2025PubMed Verified

26. 26.
    Predictors of response and enteral autonomy in children with short bowel syndrome treated with teduglutide: a real-life multicentre cohort study

    Norsa L, Ghirardi A, Ramos Boluda E, Guz-Mark A, Hojsak I, Hilberath J et al. · EClinicalMedicine · 2025PubMed Verified

27. 27.
    Teduglutide in adults with short bowel syndrome and intestinal failure: A descriptive cohort study

    Low ESL, Burrell K, Tan K, Chapman B, Testro A, Wong D · JPEN. Journal of parenteral and enteral nutrition · 2025PubMed Verified

28. 28.
    Identification of Pappalysin-2 (PAPP-A2), a modulator of Insulin-like Growth Factor-1 pathway, as a potential marker of teduglutide efficacy in patients with short bowel syndrome

    de Dreuille B, Nicolle R, Cros J, Cazals-Hatem D, Chassac A, Poté N et al. · Clinical nutrition (Edinburgh, Scotland) · 2025PubMed Verified

29. 29.
    Updates in Intestinal Failure Management

    Wang SZ, O'Daniel EL · Journal of clinical medicine · 2025ReviewPubMed Verified

30. 30.
    Development of a Mechanism of Action-Reflective Cell-Based Reporter Gene Assay for Measuring Bioactivities of Therapeutic Glucagon-like Peptide-2 Analogues

    Zhang X, Li C, Deng Z, Liang C, Li J · Molecules (Basel, Switzerland) · 2025PubMed Verified

31. 31.
    Review of cost-effectiveness analysis to study pediatric intestinal failure and transplant

    Raghu VK, Smith KJ · Intestinal Failure (New York, N.Y.) · 2024PubMed Verified

32. 32.
    Teduglutide for treatment-refractory severe intestinal acute graft-versus-host disease - a multicenter survey

    Brehm N, Biavasco F, Clausen J, Jung J, Maas-Bauer K, Wäsch R et al. · Bone marrow transplantation · 2025PubMed Verified

33. 33.
    Comprehensive analysis of adverse drug reactions associated with teduglutide: post-marketing insights and safety implications

    Kudaravalli P, Andrews MB, Adler DG · Expert opinion on drug safety · 2025PubMed Verified

34. 34.
    Drug-induced kidney stones: a real-world pharmacovigilance study using the FDA adverse event reporting system database

    Ding P, Luo Q, Cao L · Frontiers in pharmacology · 2025PubMed Verified

35. 35.
    European Consensus on Malabsorption-UEG & SIGE, LGA, SPG, SRGH, CGS, ESPCG, EAGEN, ESPEN, and ESPGHAN. Part 1: Definitions, Clinical Phenotypes, and Diagnostic Testing for Malabsorption

    Lenti MV, Hammer HF, Tacheci I, Burgos R, Schneider S, Foteini A et al. · United European gastroenterology journal · 2025PubMed Verified

36. 36.
    Corrigendum to "Real-world experience of Teduglutide use in adults with short bowel syndrome: A seven-year international multicenter survey" Clin Nutr 2025 Feb 17:47:54-67

    Joly F, Jezerski D, Pape UF, Crivelli A, Hütterer E, Bergoin C et al. · Clinical nutrition (Edinburgh, Scotland) · 2025PubMed Verified

37. 37.
    GLP-2 prevents antipsychotics-induced metabolic dysfunction in mice

    Peng Y, Feng C, Peng S, Wang Y, Zhang Q, Jiao Z et al. · Nature metabolism · 2025PubMed Verified

38. 38.
    Glucagon-like peptide-2 pharmacotherapy activates hepatic Farnesoid X receptor-signaling to attenuate resection-associated bile acid loss in mice

    Reiner J, Mohebali N, Kurth J, Witte M, Prehn C, Lindner T et al. · Molecular metabolism · 2025PubMed Verified

39. 39.
    European Consensus on Malabsorption-UEG & SIGE, LGA, SPG, SRGH, CGS, ESPCG, EAGEN, ESPEN, and ESPGHAN: Part 2: Screening, Special Populations, Nutritional Goals, Supportive Care, Primary Care Perspective

    Lenti MV, Hammer HF, Tacheci I, Burgos R, Schneider S, Foteini A et al. · United European gastroenterology journal · 2025PubMed Verified

40. 40.
    Short bowel syndrome and d-lactic acidosis: A case report with supplemental home parenteral nutrition and teduglutide

    Carrillo-López E, Tapia-Sanchiz MS, Jiménez-Blanco S, Molina-Baena B · Endocrinologia, diabetes y nutricion · 2025Case ReportPubMed Verified

41. 41.
    Survival and parenteral nutrition dependence in patients aged 65 y and older with short bowel syndrome: a retrospective observational cohort study

    Draullette M, de Dreuille B, Sanchez M, Bataille J, Billiauws L, Nuzzo A et al. · The American journal of clinical nutrition · 2025PubMed Verified

42. 42.
    Successful treatment with teduglutide for an adolescent with cerebral palsy accompanied by short bowel syndrome

    Tsuji M, Ikeda A, Tsuyusaki Y, Goto T, Iai M · Pediatrics international : official journal of the Japan Pediatric Society · 2025PubMed Verified

43. 43.
    Real-world experience of Teduglutide use in adults with short bowel syndrome: A seven-year international multicenter survey

    Joly F, Jezerski D, Pape UF, Crivelli A, Hütterer E, Bergoin C et al. · Clinical nutrition (Edinburgh, Scotland) · 2025PubMed Verified

44. 44.
    Successful Pregnancy in a Patient with Crohn's Disease and Short Bowel Syndrome: Off Total Parenteral Nutrition and On Teduglutide, a Glucagon-Like Peptide-2 Analog - A Case Report

    Dahar MM, Both M, Lord LM, Densmore C, Saubermann LJ · Case reports in gastroenterology · 2025PubMed Verified

45. 45.
    Glucagon-like peptides agonists promote maturation of intestinal organoids derived from neonates with necrotizing enterocolitis

    Biouss G, Lee C, Li B, Adeli K, Pierro A · Pediatric surgery international · 2025PubMed Verified

46. 46.
    Encapsulation of hydrophobically ion-paired teduglutide in nanoemulsions: Effect of anionic counterions

    Jeon Y, Kim SG, Choi KO, Park JT · Food chemistry · 2025PubMed Verified

47. 47.
    Forty-eight months outcomes of teduglutide treatment in adult stable patients with short bowel syndrome and home parenteral nutrition dependence: A real-world Italian single-center observational cohort study

    Mazzuoli S, Regano N, Lamacchia S, Silvestri A, Guglielmi FW · Nutrition (Burbank, Los Angeles County, Calif.) · 2025PubMed Verified

48. 48.
    Therapeutic interventions targeting enteropathy in severe acute malnutrition modulate systemic and vascular inflammation and epithelial regeneration

    Sturgeon JP, Mutasa K, Bwakura-Dangarembizi M, Amadi B, Ngosa D, Dzikiti A et al. · EBioMedicine · 2025RCTPubMed Verified

49. 49.
    Novel homozygous nonsense mutation in glucagon-like peptide-2 receptor gene resulting in severe human illness

    Jaramishian C, Kamal S, Martín MG, Minkoff NZ · JPGN reports · 2024PubMed Verified

50. 50.
    Real-life experience of teduglutide use in pediatric patients with short bowel syndrome in Argentina. A multicenter study

    Martínez MI, Busoni V, Saure C, Dlugosewsky C, Dalieri M, Cosentino S et al. · Intestinal Failure (New York, N.Y.) · 2024PubMed Verified